Another important aspect is whether the beneficial effects of GLP-1 RA and SGLT-2 inhibitors are present in people without established CVD, early in the course of dysglycemia, e. g., the insulin-resistant state and in pre-diabetes. This evidence concerns the gene INS and diabetes mellitus.